Loading clinical trials...
Loading clinical trials...
The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the op...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
AstraZeneca
NCT05877196 · Mild Cognitive Impairment, Alzheimer Disease, and more
NCT07545473 · Dementia, Neurodegenerative Diseases, and more
NCT04570085 · Alzheimer Disease
NCT07531732 · Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
NCT06501495 · Aging, Alzheimer Disease
Research Site
Graz, Osterreich
Research Site
Innsbruck, Osterreich
Research Site
Vienna, Osterreich
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions